Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis (Q36786067)

16 August 2017

1 reference

title

Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis (English)

1 reference

16 August 2017

Yihai Cao

1

1 reference

16 August 2017

Qi Liu

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Advances in Cancer Research

16 August 2017

published in

1 reference

16 August 2017

volume

97

1 reference

16 August 2017

page(s)

203-224

1 reference

Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Focus on lymphangiogenesis in tumor metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Lymphangiogenesis in development and human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

EGCG, a major component of green tea, inhibits VEGF production by swine granulosa cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Comparative Evaluation of FGF-2–, VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Endogenous angiogenesis inhibitors and their therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Immunological consequences of macrophage-mediated clearance of apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiogenesis inhibited by drinking tea.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vascular endothelial growth factor C induces angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Antiangiogenic mechanisms of diet-derived polyphenols

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF gene therapy: stimulating angiogenesis or angioma-genesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiogenesis in life, disease and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

A new notch in the HIF belt: how hypoxia impacts differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Dose-dependent response of FGF-2 for lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Functions of the VEGF receptor-1 (FLT-1) in the vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Pigment epithelium–derived factor regulates the vasculature and mass of the prostate and pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

1 reference

7 January 2021

Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Small GTP-Binding Protein Rac Is an Essential Mediator of Vascular Endothelial Growth Factor-Induced Endothelial Fenestrations and Vascular Permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Different pathways of macromolecule extravasation from hyperpermeable tumor vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

The role of vascular endothelial growth factor in pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vasculogenic mimicry and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Endogenous angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Hypoxia requires notch signaling to maintain the undifferentiated cell state

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Hepatocyte growth factor promotes lymphatic vessel formation and function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiostatin binds ATP synthase on the surface of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

In vivo absence of synergism between fibroblast growth factor-2 and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Endogenous inhibitors of angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Current biology of VEGF-B and VEGF-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Pegaptanib and age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Polymeric system for dual growth factor delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Properties of Two VEGF Receptors, Flt-1 and KDR, in Signal Transductiona

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

New roles for Src kinases in control of cell survival and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Vascular permeability factor (VPF, VEGF) in tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Bevacizumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Angiogenesis: where do we stand now?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2997009-2

7 January 2021

10.1016/S0065-230X(06)97009-2

Identifiers

DOI

1 reference

16 August 2017

1 reference